
  
    
      
        Health_NNP Benefits_NNP of_IN Physical_NNP Activity_NN
        Regular_JJ physical_JJ activity_NN has_VBZ been_VBN recognized_VBN to_TO confer_VB health_NN benefits_NNS since_IN antiquity_NN
        [_NN 1_CD ]_NN ._. However_RB ,_, for_IN most_JJS of_IN humankind_NN ,_, voluntary_JJ discretion_NN over_IN whether_IN or_CC not_RB to_TO exercise_VB
        is_VBZ a_DT recent_JJ phenomenon_NN limited_VBN to_TO advanced_VBD industrialized_VBN societies_NNS ._.
        A_DT large_JJ body_NN of_IN epidemiological_JJ literature_NN consistently_RB documents_VBZ greater_JJR longevity_NN in_IN
        persons_NNS who_WP are_VBP physically_RB active_JJ on_IN a_DT near-daily_JJ basis_NN ,_, and_CC reveals_VBZ inverse_NN relationships_NNS
        between_IN levels_NNS of_IN daily_JJ exercise_NN and_CC incidence_NN of_IN major_JJ chronic_JJ disorders_NNS such_JJ as_IN obesity_NN
        [_NN 2_CD ]_NN ,_, hypertension_NN [_NN 3_CD ]_NN ,_, diabetes_NN [_NN 4_CD ]_NN ,_, ischemic_JJ heart_NN disease_NN ,_, and_CC all_DT causes_NNS of_IN mortality_NN
        [_NN 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._. From_IN a_DT public_JJ health_NN perspective_NN ,_, there_EX is_VBZ little_JJ question_NN that_IN even_RB
        modest_JJ increases_NNS in_IN daily_JJ activities_NNS such_JJ as_IN walking_VBG or_CC stair_NN climbing_VBG would_MD have_VB important_JJ
        positive_JJ consequences_NNS in_IN reducing_VBG the_DT burden_NN of_IN illness_NN ._.
        However_RB ,_, knowledge_NN of_IN the_DT likely_JJ health_NN benefits_NNS accruing_VBG to_TO the_DT physically_RB active_JJ so_RB
        far_RB has_VBZ not_RB been_VBN a_DT sufficient_JJ stimulus_NN to_TO promote_VB sustained_VBN changes_NNS in_IN behavior_NN for_IN most_JJS of_IN
        the_DT American_JJ population_NN ._. If_IN education_NN and_CC public_JJ policies_NNS are_VBP insufficient_JJ to_TO promote_VB
        behavioral_JJ changes_NNS to_TO increase_VB physical_JJ activity_NN among_IN most_JJS people_NNS ,_, can_MD advances_NNS in_IN
        biotechnology_NN confer_VB such_JJ benefits_NNS to_TO individuals_NNS unable_JJ or_CC unwilling_JJ to_TO perform_VB the_DT
        necessary_JJ physical_JJ effort_NN ?_.
      
      
        Translating_NNP Knowledge_NNP of_IN Exercise_NNP Biology_NNP to_TO Novel_NNP Therapeutics_NNP
        Greater_NNP knowledge_NN of_IN how_WRB cells_NNS and_CC tissues_NNS are_VBP modified_VBN in_IN response_NN to_TO recurring_VBG bouts_NNS
        of_IN exercise_NN provides_VBZ a_DT basis_NN for_IN more_JJR precise_JJ recommendations_NNS as_IN to_TO the_DT mode_NN ,_, intensity_NN ,_,
        and_CC amount_NN of_IN exercise_NN required_VBN to_TO produce_VB specific_JJ health_NN benefits_NNS (_( e_SYM ._. g_SYM ._. ,_, treatment_NN of_IN
        dyslipidemia_NN [_NN 13_CD ]_NN ,_, control_NN of_IN body_NN weight_NN [_NN 14_CD ]_NN ,_, or_CC prevention_NN of_IN diabetes_NN [_NN 15_CD ]_NN )_) ._. In_IN
        addition_NN ,_, an_DT understanding_NN of_IN the_DT molecular_JJ signaling_VBG events_NNS that_WDT drive_NN the_DT beneficial_JJ
        effects_NNS of_IN exercise_NN on_IN human_JJ physiology_NN could_MD foster_VB the_DT development_NN of_IN novel_NN drugs_NNS ,_,
        devices_NNS ,_, or_CC biological_JJ agents_NNS designed_VBN to_TO substitute_VB for_IN exercise_NN ._.
        Many_JJ individuals_NNS who_WP otherwise_RB would_MD develop_VB diabetes_NN or_CC cardiovascular_JJ disease_NN would_MD
        benefit_VB if_IN advances_NNS in_IN exercise_NN biology_NN revealed_VBD novel_NN measures_NNS to_TO promote_VB the_DT favorable_JJ
        effects_NNS on_IN insulin_NN sensitivity_NN ,_, lipoprotein_NN metabolism_NN ,_, and_CC blood_NN pressure_NN that_WDT are_VBP known_VBN
        to_TO accrue_VB through_IN regular_JJ physical_JJ activity_NN ._.
      
      
        Physiological_NNP Properties_NNP of_IN Skeletal_NNP Muscle_NNP
        What_WP do_VBP we_PRP know_VBP about_IN basic_JJ muscle_NN and_CC exercise_NN biology_NN ?_. The_DT cells_NNS that_WDT constitute_VBP our_PRP$
        skeletal_NN muscles_NNS are_VBP called_VBN myofibers—large_NN multinucleated_JJ cells_NNS that_WDT may_MD extend_VB for_IN the_DT
        full_JJ length_NN of_IN individual_JJ muscles_NNS ._. There_EX are_VBP different_JJ types_NNS of_IN myofibers_NNS ,_, which_WDT vary_VBP in_IN
        size_NN and_CC with_IN respect_NN to_TO metabolic_JJ and_CC contractile_NN capability_NN [_NN 16_CD ]_NN (_( Figure_NN 1_LS )_) ._. Skeletal_NNP
        myofibers_NNS are_VBP innervated_JJ by_IN motor_NN neurons_NNS that_WDT contact_NN each_DT myofiber_NN ,_, and_CC the_DT intensity_NN ,_,
        duration_NN ,_, and_CC timing_NN of_IN each_DT muscle_NN contraction_NN are_VBP determined_VBN by_IN the_DT pattern_NN of_IN motor_NN
        neuron_NN firing_NN ._. A_DT pattern_NN of_IN occasional_JJ intense_JJ contractions_NNS separated_VBN by_IN longer_JJR periods_NNS of_IN
        rest_NN is_VBZ called_VBN “ phasic_JJ ,_,” while_IN a_DT pattern_NN characterized_VBN by_IN brief_JJ contractions_NNS occurring_VBG
        repeatedly_RB over_IN an_DT extended_VBN period_NN is_VBZ called_VBN “ tonic_NN ._.” Endurance_NNP training_NN regimens_NNS like_IN
        running_VBG or_CC cycling_VBG employ_VB tonic_NN patterns_NNS of_IN contractile_NN work_NN ,_, and_CC it_PRP is_VBZ this_DT form_NN of_IN
        habitual_NN activity_NN that_WDT serves_VBZ best_JJS to_TO reduce_VB risk_NN for_IN obesity_NN ,_, diabetes_NN ,_, hypertension_NN ,_, and_CC
        heart_NN disease_NN ._.
      
      
        Dynamics_NNP of_IN Muscle_NNP Mass_NNP
        Maintenance_NNP of_IN normal_JJ muscle_NN mass_NN requires_VBZ some_DT minimal_JJ level_NN of_IN ongoing_JJ work_NN activity_NN ,_,
        and_CC building_NN and_CC maintaining_VBG muscle_NN mass_NN is_VBZ most_RBS effectively_RB done_VBN through_IN phasic_JJ
        contractions_NNS ._. A_DT slow_JJ but_CC inexorable_JJ loss_NN of_IN muscle_NN mass_NN is_VBZ a_DT feature_NN of_IN advancing_VBG age_NN in_IN
        human_JJ populations_NNS [_NN 17_CD ]_NN ._. Loss_NN of_IN muscle_NN mass_NN and_CC strength_NN is_VBZ an_DT important_JJ determinant_NN of_IN
        injury_NN and_CC disability_NN in_IN the_DT elderly_JJ ,_, but_CC even_RB rigorous_JJ weight_NN training_NN programs_NNS cannot_NN
        completely_RB counteract_VB this_DT age-related_JJ decline_NN that_WDT becomes_VBZ particularly_RB troublesome_JJ in_IN the_DT
        eighth_JJ and_CC ninth_JJ decades_NNS of_IN life_NN ._. Efforts_NNS to_TO develop_VB effective_JJ countermeasures_NNS to_TO maintain_VB
        muscle_NN mass_NN in_IN the_DT elderly_JJ constitute_VBP an_DT active_JJ and_CC important_JJ area_NN of_IN current_JJ research_NN
        [_NN 18_CD ,_, 19_CD ,_, 20_CD ]_NN ._.
        Although_IN the_DT molecular_JJ signaling_VBG mechanisms_NNS that_WDT transduce_NN the_DT effects_NNS of_IN phasic_JJ
        patterns_NNS of_IN work_NN activity_NN to_TO modify_VB muscle_NN mass_NN are_VBP incompletely_RB understood_VBN ,_, recent_JJ
        evidence_NN implicates_NNS pathways_NNS that_WDT include_VBP the_DT signaling_VBG molecules_NNS PI_NNP 3_CD kinase_NN ,_, Akt_NNP ,_, mTOR_NN ,_,
        S_NNP 6_CD K_NNP ,_, and_CC ERK_NNP ,_, the_DT ubiquitin_NN ligases_NNS MAFbx_NNP and_CC MuRF_NNP 1_CD ,_, and_CC transcription_NN factors_NNS of_IN the_DT FOX_NN
        superfamily_RB in_IN the_DT control_NN of_IN both_DT catabolic_JJ and_CC anabolic_JJ processes_VBZ [_NN 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ]_NN ._.
      
      
        Contractile_NNP and_CC Metabolic_NNP Properties_NNP
        With_IN respect_NN to_TO variations_NNS in_IN contractile_NN and_CC metabolic_JJ properties_NNS ,_, myofibers_NNS are_VBP
        classified_VBN on_IN a_DT spectrum_NN between_IN two_CD extremes_NNS on_IN the_DT basis_NN of_IN contractile_NN (_( fast_RB versus_CC
        slow_JJ )_) and_CC metabolic_JJ (_( glycolytic_JJ versus_CC oxidative_JJ )_) properties_NNS ._. At_IN one_CD extreme_JJ ,_, the_DT fastest_JJS
        glycolytic_JJ fibers_NNS have_VBP high_JJ levels_NNS of_IN enzymes_NNS that_WDT generate_VBP ATP_NNP via_IN glycolysis_NNS but_CC few_JJ
        mitochondria_NN (_( approximately_RB 1_CD %_NN of_IN cell_NN volume_NN )_) ._. At_IN the_DT other_JJ end_NN of_IN the_DT spectrum_NN ,_, slow_JJ
        oxidative_JJ fibers_NNS generate_VBP force_NN with_IN slower_JJR kinetics_NNS but_CC are_VBP capable_JJ of_IN long_JJ periods_NNS of_IN
        repeated_VBN contraction_NN without_IN fatigue_NN ._. They_PRP are_VBP rich_JJ in_IN mitochondria_NN (_( 3_CD %_NN –_NN 10_CD %_NN of_IN cell_NN
        volume_NN )_) ._. Other_JJ myofibers_NNS ,_, called_VBD fast_RB oxidative_JJ ,_, are_VBP both_DT relatively_RB fast_RB and_CC resistant_JJ to_TO
        fatigue_NN ,_, and_CC are_VBP rich_JJ in_IN mitochondria_NN (_( like_IN the_DT slow_JJ oxidative_JJ fibers_NNS )_) ._. Muscles_NNP composed_VBN
        primarily_RB of_IN fast_RB glycolytic_JJ fibers_NNS are_VBP needed_VBN for_IN rapid_JJ movements_NNS (_( e_SYM ._. g_SYM ._. ,_, escape_VB from_IN
        predators_NNS )_) but_CC fatigue_NN when_WRB sustained_VBN periods_NNS of_IN activity_NN are_VBP required_VBN (_( e_SYM ._. g_SYM ._. ,_,
        migration_NN )_) ._.
        Most_JJS human_JJ muscles_NNS exhibit_NN a_DT mosaic_JJ pattern_NN of_IN different_JJ fiber_NN types_NNS (_( Figure_NN 1_LS )_) ,_, with_IN a_DT
        great_JJ deal_NN of_IN variation_NN among_IN individuals_NNS ,_, which_WDT is_VBZ influenced_VBN at_IN least_JJS in_IN part_NN by_IN patterns_NNS
        of_IN use_NN ._. When_WRB we_PRP exercise_VBP daily_JJ ,_, or_CC at_IN least_JJS several_JJ times_NNS weekly_JJ ,_, we_PRP deliver_VBP a_DT stimulus_NN to_TO
        the_DT specific_JJ muscle_NN groups_NNS involved_VBN in_IN these_DT activities_NNS that_WDT is_VBZ sufficient_JJ to_TO alter_VB
        specialized_JJ properties_NNS of_IN myofibers_NNS within_IN these_DT muscles_NNS ._. While_IN habitual_NN physical_JJ activity_NN
        promotes_VBZ a_DT great_JJ variety_NN of_IN physiological_JJ adaptations_NNS that_WDT alter_VBP vascular_NN reactivity_NN ,_,
        cardiac_JJ function_NN ,_, adipocyte_NN function_NN ,_, and_CC neurophysiology_NN ,_, adaptive_JJ responses_NNS of_IN skeletal_NN
        myofibers_NNS confer_VBP at_IN least_JJS some_DT of_IN the_DT health_NN benefits_NNS ._.
        Patterning_NNP of_IN skeletal_NN muscle_NN fiber_NN composition_NN is_VBZ initially_RB determined_VBN during_IN embryonic_JJ
        development_NN ,_, but_CC can_MD be_VB partially_RB or_CC completely_RB overturned_VBN by_IN stimuli_NNS applied_VBN to_TO fully_RB
        mature_VBP adult_NN myofibers_NNS :_: by_IN hormonal_NN influences_VBZ (_( e_SYM ._. g_SYM ._. ,_, thyroid_NN hormone_NN )_) ,_, but_CC most_RBS
        importantly_RB by_IN different_JJ patterns_NNS of_IN motor_NN nerve_NN activity_NN and_CC contractile_NN work_NN ._. Myofibers_NNP
        that_DT experience_NN phasic_JJ patterns_NNS of_IN contractile_NN work—brief_NN bursts_NNS of_IN activity_NN interspersed_VBN
        within_IN long_JJ periods_NNS of_IN inactivity—will_NN assume_VBP the_DT fast_RB glycolytic_JJ phenotype_NN ._. Myofibers_NNP
        subjected_VBN to_TO tonic_NN patterns_NNS of_IN work_NN activity—sustained_JJ periods_NNS of_IN repetitive_JJ contraction_NN on_IN
        a_DT habitual_NN basis—will_NN take_NN on_IN fast_RB oxidative_JJ or_CC slow_JJ oxidative_JJ properties_NNS ._. Under_IN
        experimental_JJ conditions_NNS in_IN laboratory_NN animals_NNS ,_, it_PRP is_VBZ possible_JJ to_TO transform_VB muscles_NNS
        completely_RB from_IN one_CD myofiber_NN phenotype_NN to_TO another_DT in_IN a_DT reversible_JJ manner_NN ,_, solely_RB by_IN
        altering_VBG the_DT pattern_NN of_IN neural_NN stimulation_NN ._. We_PRP know_VBP that_IN having_VBG a_DT high_JJ proportion_NN of_IN
        oxidative_JJ muscle_NN fibers_NNS conveys_VBZ health_NN benefits_NNS ,_, and_CC the_DT possibility_NN to_TO control_VB fiber_NN
        composition_NN through_IN therapeutic_JJ intervention_NN is_VBZ promising_JJ ._.
      
      
        Molecular_NNP Signaling_NNP Pathways_NNP
        At_IN a_DT cellular_JJ and_CC molecular_JJ level_NN ,_, how_WRB does_VBZ a_DT fast_RB glycolytic_JJ myofiber_NN sense_NN a_DT tonic_NN
        pattern_NN of_IN contractile_NN activity_NN and_CC transduce_NN that_DT information_NN to_TO transform_VB itself_PRP into_IN a_DT
        cell_NN with_IN fast_RB oxidative_JJ or_CC slow_JJ oxidative_JJ properties_NNS ?_. We_PRP know_VBP that_IN such_JJ signals_NNS must_MD be_VB
        transduced_JJ to_TO the_DT nucleus_NN ,_, activating_VBG certain_JJ genes_NNS and_CC suppressing_VBG others_NNS ,_, for_IN myofiber_NN
        plasticity_NN to_TO occur_VB ._. We_PRP know_VBP the_DT identities_NNS of_IN some_DT of_IN the_DT nuclear_JJ transcription_NN factors_NNS
        that_WDT carry_VBP these_DT signals_NNS ,_, and_CC of_IN other_JJ proteins_NNS that_WDT regulate_VB the_DT function_NN of_IN these_DT
        transcription_NN factors_NNS (_( Figure_NN 2_LS )_) ._.
        Quite_RB a_DT variety_NN of_IN intracellular_NN messengers_NNS have_VBP been_VBN proposed_VBN to_TO provide_VB the_DT proximate_NN
        signals_NNS in_IN exercising_VBG muscles_NNS to_TO stimulate_VB activity-dependent_JJ gene_NN regulation_NN ._. This_DT
        discussion_NN will_MD focus_VB on_IN a_DT signaling_VBG cascade_NN mediated_JJ by_IN calcineurin_NN ,_, a_DT calcium-regulated_JJ
        protein_NN phosphatase_NN that_IN signals_NNS to_TO the_DT nucleus_NN via_IN transcription_NN factors_NNS of_IN the_DT nuclear_JJ
        factor_NN of_IN activated_VBN T_NN cells_NNS (_( NFAT_NNP )_) family_NN ._. Upon_IN receipt_NN of_IN the_DT appropriate_JJ calcium_NN signal_NN ,_,
        calcineurin_NN is_VBZ activated_VBN and_CC removes_VBZ phosphate_NN groups_NNS from_IN NFAT_NNP ,_, thereby_RB permitting_VBG
        translocation_NN of_IN NFAT_NNP to_TO the_DT nucleus_NN ._. Within_IN the_DT nucleus_NN ,_, NFAT_NNP binds_NNS DNA_NNP and_CC activates_NNS
        transcription_NN (_( in_IN concert_NN with_IN other_JJ transcription_NN factors_NNS )_) of_IN relevant_JJ downstream_JJ target_NN
        genes_NNS that_WDT encode_NN proteins_NNS necessary_JJ for_IN fast_RB oxidative_JJ or_CC slow_JJ oxidative_JJ myofiber_NN
        phenotypes_NNS ._.
        Calcineurin_NNP and_CC NFAT_NNP proteins_NNS are_VBP abundant_JJ in_IN skeletal_NN myofibers_NNS ,_, and_CC several_JJ lines_NNS of_IN
        evidence_NN support_NN the_DT viewpoint_NN that_IN the_DT calcineurin–_NN NFAT_NNP pathway_NN plays_VBZ a_DT role_NN in_IN mediating_VBG
        activity-dependent_JJ gene_NN regulation_NN in_IN muscle_NN
        [_NN 25_CD ,_, 26_CD ,_, 27_CD ,_, 28_CD ,_, 29_CD ,_, 30_CD ,_, 31_CD ,_, 32_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ,_, 36_CD ,_, 37_CD ,_, 38_CD ,_, 39_CD ]_NN ._. For_IN example_NN ,_, in_IN mice_NNS genetically_RB engineered_VBN
        to_TO distinguish_VB the_DT inactive_JJ (_( cytoplasmic_JJ )_) from_IN active_JJ (_( nuclear_JJ )_) forms_NNS of_IN NFAT_NNP by_IN means_NNS of_IN a_DT
        sensor_NN ,_, it_PRP is_VBZ evident_JJ that_IN NFAT_NNP is_VBZ inactive_JJ in_IN resting_VBG muscles_NNS ,_, but_CC activated_VBN by_IN tonic_NN
        patterns_NNS of_IN muscle_NN contraction_NN (_( running_VBG or_CC electrical_JJ stimulation_NN of_IN the_DT motor_NN nerve_NN )_) [_NN 40_CD ]_NN ._.
        Using_VBG other_JJ genetic_JJ manipulations_NNS in_IN mice_NNS to_TO produce_VB in_IN muscle_NN a_DT form_NN of_IN calcineurin_NN that_WDT
        remains_VBZ active_JJ even_RB in_IN the_DT absence_NN of_IN calcium_NN signals_NNS ,_, myofibers_NNS are_VBP converted_VBN from_IN fast_RB
        glycolytic_JJ to_TO fast_RB oxidative_JJ or_CC slow_JJ oxidative_JJ forms_NNS [_NN 41_CD ]_NN ._. And_CC in_IN muscles_NNS of_IN mice_NNS
        genetically_RB engineered_VBN to_TO lack_NN calcineurin_NN ,_, fiber_NN type_NN switching_VBG is_VBZ impaired_VBN [_NN 42_CD ]_NN ._.
      
      
        Cellular_NNP Memory_NN
        Muscle_NNP contractions_NNS are_VBP initiated_VBN under_IN the_DT influence_NN of_IN the_DT motor_NN nerve_NN by_IN release_NN of_IN
        calcium_NN from_IN the_DT sarcoplasmic_JJ reticulum_NN ,_, which_WDT triggers_VBZ actin–myosin_NN crossbridge_NN cycling_NN
        (_( Figure_NN 3_LS )_) ._. Calcium_NNP released_VBD via_IN ryanodine_NN receptors_NNS is_VBZ completely_RB sufficient_JJ to_TO activate_VBP
        muscle_NN contractions_NNS ,_, and_CC the_DT effects_NNS are_VBP immediate_JJ (_( within_IN milliseconds_NNS )_) ._. It_PRP is_VBZ also_RB
        sufficient_JJ to_TO initiate_VB calcineurin–_NN NFAT_NNP signaling_VBG to_TO the_DT nucleus_NN ,_, but_CC cannot_NN by_IN itself_PRP
        sustain_VB the_DT signal_NN in_IN a_DT manner_NN necessary_JJ to_TO promote_VB myofiber_NN remodeling_VBG [_NN 40_CD ]_NN ._. Changes_NNS in_IN
        gene_NN expression_NN evoked_JJ by_IN neuromuscular_NN activity_NN are_VBP not_RB immediate_JJ but_CC require_VB that_IN the_DT
        stimulus_NN be_VB sustained_VBN for_IN an_DT extended_VBN period_NN (_( minutes_NNS to_TO hours_NNS )_) ._. Moreover_RB ,_, tonic_NN
        stimulation_NN of_IN the_DT motor_NN nerve_NN must_MD be_VB repeated_VBN daily_JJ ,_, or_CC nearly_RB so_RB ,_, over_IN several_JJ weeks_NNS for_IN
        the_DT changes_NNS in_IN myofiber_NN properties_NNS to_TO become_VB fully_RB manifest_JJ ._. We_PRP have_VBP characterized_VBN this_DT
        requirement_NN for_IN repetition_NN of_IN the_DT activity_NN stimulus_NN over_IN days_NNS as_IN a_DT form_NN of_IN “ cellular_JJ
        memory_NN ._.” The_DT effects_NNS of_IN the_DT tenth_NN or_CC 20_CD th_NN day_NN of_IN exercise_NN are_VBP not_RB the_DT same_JJ as_IN the_DT effects_NNS
        of_IN the_DT first_JJ day_NN ._. The_DT myofiber_NN somehow_RB “ remembers_VBZ” not_RB only_RB the_DT pattern_NN of_IN activity_NN it_PRP has_VBZ
        experienced_VBN today_NN ,_, but_CC what_WP has_VBZ gone_VBN on_IN over_IN the_DT preceding_VBG days_NNS or_CC weeks_NNS ,_, such_JJ that_IN the_DT
        changes_NNS in_IN abundance_NN of_IN proteins_NNS that_WDT control_NN contractile_NN function_NN and_CC metabolism_NN accrue_VB
        over_IN time_NN ._.
        To_TO explain_VB this_DT cellular_JJ memory_NN ,_, we_PRP propose_VBP that_RB ,_, as_IN the_DT bursts_NNS of_IN contractile_NN activity_NN
        are_VBP sustained_VBN over_IN time_NN (_( through_IN a_DT tonic_NN pattern_NN of_IN neural_NN stimulation_NN )_) ,_, a_DT second_JJ source_NN of_IN
        calcium_NN is_VBZ mobilized_VBN from_IN outside_IN of_IN the_DT cell_NN and_CC enters_VBZ via_IN a_DT class_NN of_IN calcium_NN channels_NNS
        that_WDT are_VBP called_VBN “ store-operated_JJ” or_CC “ non-voltage-dependent_JJ ._.” This_DT second_JJ source_NN of_IN calcium_NN
        is_VBZ not_RB required_VBN for_IN muscle_NN contractions_NNS ,_, but_CC is_VBZ required_VBN to_TO sustain_VB calcium-dependent_JJ
        signaling_VBG to_TO the_DT nucleus_NN ._. Phasic_NNP patterns_NNS of_IN contractile_NN activity_NN do_VBP not_RB promote_VB calcium_NN
        entry_NN via_IN store-operated_JJ channels_NNS ._. Tonic_NNP patterns_NNS of_IN activity_NN ,_, in_IN contrast_NN ,_, would_MD not_RB only_RB
        promote_VB the_DT mobilization_NN of_IN extracellular_NN calcium_NN but_CC also_RB increase_VB the_DT number_NN of_IN
        store-operated_JJ calcium_NN channels_NNS with_IN each_DT bout_NN of_IN exercise_NN ._. Myofibers_NNP would_MD thereby_RB grow_VB
        progressively_RB more_RBR responsive_JJ to_TO tonic_NN activity_NN ._. Consistent_NNP with_IN this_DT model_NN ,_, we_PRP know_VBP that_IN
        daily_JJ running_NN increases_VBZ the_DT expression_NN of_IN a_DT putative_JJ store-operated_JJ calcium_NN channel_NN called_VBD
        TRPC_NNP 3_CD ._. Moreover_RB ,_, increasing_VBG the_DT abundance_NN of_IN TRPC_NNP 3_CD in_IN cultured_JJ myotubes_NNS prolongs_NNS the_DT period_NN
        in_IN which_WDT intracellular_NN calcium_NN is_VBZ elevated_VBD following_VBG a_DT depolarizing_VBG stimulus_NN ,_, sustains_VBZ the_DT
        transcription_NN factor_NN NFAT_NNP within_IN the_DT nucleus_NN ,_, and_CC augments_NNS expression_NN of_IN NFAT-dependent_NNP
        target_NN genes_NNS [_NN 40_CD ]_NN ._.
        A_DT great_JJ deal_NN of_IN additional_JJ research_NN remains_VBZ to_TO be_VB done_VBN before_IN we_PRP have_VBP a_DT comprehensive_JJ
        understanding_NN of_IN how_WRB habitual_NN physical_JJ activity_NN promotes_VBZ changes_NNS in_IN gene_NN expression_NN in_IN
        skeletal_NN muscles_NNS ,_, and_CC in_IN turn_NN improves_VBZ fitness_NN and_CC reduces_VBZ risk_NN for_IN diabetes_NN ,_, hypertension_NN ,_,
        dyslipidemia_NN ,_, and_CC coronary_JJ artery_NN disease_NN ._. However_RB ,_, studies_NNS of_IN the_DT relationships_NNS between_IN
        the_DT proteins_NNS of_IN calcium_NN metabolism_NN and_CC calcium-regulated_JJ signaling_VBG pathways—as_NNS described_VBD
        here_RB in_IN a_DT simplified_VBN manner_NN with_IN respect_NN to_TO TRPC_NNP 3_CD ,_, calcineurin_NN ,_, and_CC NFAT_NNP proteins—are_NN
        illustrative_JJ of_IN progress_NN in_IN this_DT field_NN ._. Other_JJ notable_JJ findings_NNS point_VBP to_TO additional_JJ
        signaling_VBG proteins_NNS (_( CAMK_NNP ,_, p_NN 38_CD MAPK_NNP ,_, and_CC AMPK_NNP )_) and_CC transcription_NN factors_NNS (_( PGC-_NNP 1_CD ,_, MEF_NNP 2_CD ,_, ATF_NNP 2_CD ,_,
        PPARs_NNP )_) active_JJ in_IN pathways_NNS that_WDT intersect_NN with_IN calcineurin–_NN NFAT_NNP signaling_VBG
        [_NN 31_CD ,_, 43_CD ,_, 44_CD ,_, 45_CD ,_, 46_CD ,_, 47_CD ,_, 48_CD ]_NN (_( see_VB Figure_NN 2_LS )_) ._. It_PRP is_VBZ encouraging_VBG that_IN some_DT of_IN these_DT proteins_NNS are_VBP
        attractive_JJ targets_NNS for_IN drug_NN discovery_NN ._.
      
      
        Summary_NNP and_CC Conclusions_NNP
        Long_NNP the_DT province_NN of_IN physiologists_NNS who_WP have_VBP contributed_VBN valuable_JJ insights_NNS in_IN past_JJ
        decades_NNS ,_, exercise_NN science_NN more_RBR recently_RB has_VBZ attracted_VBN the_DT attention_NN of_IN molecular_JJ
        biologists_NNS ,_, who_WP have_VBP recognized_VBN the_DT biological_JJ interest_NN and_CC medical_JJ importance_NN of_IN this_DT
        field_NN ._. Biotechnology_NNP and_CC pharmaceutical_JJ companies_NNS also_RB are_VBP beginning_VBG to_TO take_VB interest_NN ._.
        This_DT review_NN has_VBZ focused_VBN on_IN adaptive_JJ responses_NNS of_IN skeletal_NN muscle_NN to_TO changing_VBG patterns_NNS of_IN
        physical_JJ activity_NN ,_, and_CC on_IN the_DT role_NN of_IN the_DT calcium–calcineurin–_NN NFAT_NNP signaling_VBG cascade_NN in_IN
        controlling_VBG gene_NN expression_NN in_IN skeletal_NN myofibers_NNS ._. Further_RB advances_NNS in_IN our_PRP$ understanding_NN of_IN
        signaling_VBG mechanisms_NNS that_WDT govern_VBP activity-dependent_JJ gene_NN regulation_NN in_IN skeletal_NN muscle_NN
        could_MD lead_VB to_TO drugs_NNS ,_, gene_NN therapy_NN ,_, or_CC devices_NNS that_WDT can_MD ,_, at_IN least_JJS in_IN part_NN ,_, substitute_NN for_IN
        daily_JJ exercise_NN ._. Although_IN it_PRP is_VBZ unlikely_JJ that_IN such_JJ technologies_NNS would_MD fully_RB recapitulate_NN
        exercise-induced_JJ adaptations_NNS that_WDT affect_VBP other_JJ tissues_NNS of_IN the_DT body_NN ,_, beneficial_JJ effects_NNS on_IN
        work_NN performance_NN and_CC whole-body_JJ metabolism_NN have_VBP been_VBN demonstrated_VBN using_VBG gene_NN transfer_NN
        techniques_NNS to_TO alter_VB skeletal_NN muscles_NNS in_IN animal_NN models_NNS ._. If_IN it_PRP proves_VBZ possible_JJ to_TO drive_VB
        similar_JJ effects_NNS in_IN skeletal_NN muscles_NNS in_IN humans_NNS ,_, the_DT interventions_NNS capable_JJ of_IN providing_VBG such_JJ
        effects_NNS would_MD almost_RB certainly_RB find_VB broad_JJ clinical_JJ application_NN ._.
      
    
  
